Last reviewed · How we verify
GLA5PR GLARS-NF1
GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells.
GLA5PR GLARS-NF1 is a glutaminyl-tRNA synthetase (GlnRS) inhibitor designed to selectively target and inhibit neurofibromatosis type 1 (NF1) mutant cells. Used for Neurofibromatosis type 1 (NF1)-associated malignancies, NF1-associated plexiform neurofibromas.
At a glance
| Generic name | GLA5PR GLARS-NF1 |
|---|---|
| Also known as | placebo (for GLA5PR GLARS-NF1) |
| Sponsor | Daewon Pharmaceutical Co., Ltd. |
| Drug class | Glutaminyl-tRNA synthetase inhibitor |
| Target | GLARS (Glutaminyl-tRNA synthetase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug exploits a synthetic lethal interaction where NF1-deficient cells become dependent on glutaminyl-tRNA synthetase for survival. By inhibiting this enzyme, GLA5PR GLARS-NF1 selectively kills NF1-mutant tumor cells while sparing normal cells, providing a targeted approach to NF1-associated malignancies.
Approved indications
- Neurofibromatosis type 1 (NF1)-associated malignancies
- NF1-associated plexiform neurofibromas
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain (PHASE3)
- Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg (PHASE1)
- Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg (PHASE1)
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects (PHASE1)
- A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLA5PR GLARS-NF1 CI brief — competitive landscape report
- GLA5PR GLARS-NF1 updates RSS · CI watch RSS
- Daewon Pharmaceutical Co., Ltd. portfolio CI